Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201
Covered by 2 sources · 2 articles
2 outlets - including Cryptonomist and Cryptobriefing - are covering this story. Eli Lilly has placed a $40 million bet on an AI-designed injectable antibody that could change how doctors treat two conditions affecting hundreds of millions of people worldwide — and for which no approved injectable option currently exist…
All coverage
Eli Lilly’s $40M Bet on AI-Designed Injectable Antibody Sparks 36% Rally
Eli Lilly has placed a $40 million bet on an AI-designed injectable antibody that could change how doctors treat two conditions affecting hundreds of millions of people worldwide — and for which no approved injectable option currently exist…
Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201
Eli Lilly's investment in AI-designed therapeutics could revolutionize treatment options for conditions lacking effective injectable solutions. The post Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201 appeared fi…